La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Rexel a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Rexel..

Rexel (OTC:RXEEY) Azioni, Catena delle Opzioni

Rexel SA is a provider of electrical products and services to residential, nonresidential, and industrial markets. The product offering includes electrical equipment such as appliances and accessories, cables and routing, lighting, security and communication, home automation, climate control, and building management systems used in the construction, renovation, and maintenance of buildings and infrastructures. Clients include small and midsize installers, large installers and facility managers, commercial companies, and industrial customers. Rexel has three operating segments; Europe, North America, and Asia-Pacific, out of which a majority of its revenue is derived from Europe.

Rexel SA

WIIM

BBAI

BigBear.ai shares are trading lower after the company reported worse-than-expected Q3 revenue results.

Helios Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLIO#NYSE">HLIO</a>) reported quarterly earnings of $0.59 per share which beat the analyst consensus estimate of $0.54 by 9.26 percent. This is a 34.09 percent increase over earnings of $0.44 per share from the same period last year. The company reported quarterly sales of $194.500 million which missed the analyst consensus estimate of $196.574 million by 1.06 percent. This is a 3.43 percent decrease over sales of $201.400 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

HLIO

Helios Technologies Q3 2024 Adj. EPS $0.59 Beats $0.54 Estimate, Sales $194.500M Miss $196.574M Estimate

2024 ANNUAL GUIDANCE(1)
NOG is reiterating capital expenditure and production guidance and adjusting certain line items. Production taxes are being adjusted to reflect current expectations for the remainder of the year. Natural gas realizations and oil differentials are being adjusted to reflect results experienced year-to-date. Per unit cash G&amp;A is being lowered as the Company has reduced certain external expenses and continues to benefit from increasing production volumes.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Prior Guidance</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Revised Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Annual Production (Boe per day)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">120,000 - 124,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">120,000 - 124,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Annual Oil Production (Bbls per day)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">73,000 - 76,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">73,000 - 76,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Capital Expenditures ($ in millions)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$890 - $970</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$890 - $970</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Wells Turned-in-Line ("TIL")</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">93.0 - 98.0</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">93.0 - 98.0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Wells Spud</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">73.0 - 78.0</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">73.0 - 78.0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operating Expenses and Differentials:</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Production Expenses (per Boe)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$9.15 - $9.40</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$9.15 - $9.40</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Production Taxes (as a percentage of Oil &amp; Gas Sales)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">9.0% - 9.5%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">8.5% - 9.0%(2)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Average Differential to NYMEX WTI (per Bbl)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">($4.00) - ($4.85)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">($4.00) - ($4.50)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Average Realization as a Percentage of NYMEX Henry Hub (per Mcf)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">87.5% - 92.5%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">90.0% - 95.0%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">DD&amp;A Rate (per Boe)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$16.50 - $17.50</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$16.50 - $17.50</td>
</tr>
</tbody>
</table>
</figure>

Guidance

NOG Reiterates Capital Expenditure And Production Guidance

loanDepot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDI#NYSE">LDI</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.04) by 150 percent. The company reported quarterly sales of $314.598 million which beat the analyst consensus estimate of $275.995 million by 13.99 percent. This is a 18.42 percent increase over sales of $265.661 million the same period last year.

loanDepot Q3 2024 Adj. EPS $0.02 Beats $(0.04) Estimate, Sales $314.598M Beat $275.995M Estimate

SWIM

Latham Group shares are trading lower after the company reported worse-than-expected Q3 financial results and narrowed its FY24 sales guidance.

Carlyle Secured Lending (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGBD#NASDAQ">CGBD</a>) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.48 by 2.08 percent. This is a 5.77 percent decrease over earnings of $0.52 per share from the same period last year. The company reported quarterly sales of $55.97 million which missed the analyst consensus estimate of $57.54 million by 2.74 percent. This is a 7.50 percent decrease over sales of $60.50 million the same period last year.

CGBD

Carlyle Secured Lending Q3 Adj $0.49 Beats $0.48 Estimate, Sales $55.97M Miss $57.54M Estimate

GMED

Globus Medical Sees FY24 Revenue $2.49B-$2.50B Vs $2.481B Est.; Adj. Diluted EPS $2.90-$3.00 Vs $2.85 Est.

Limbach Holdings shares are trading higher after the company reported better-than-expected Q3 financial results.

MasterBrand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBC#NYSE">MBC</a>) affirms FY2024 Adj EPS guidance from $1.50-1.62 to $1.50-1.62 vs $1.49 analyst estimate..

Citigroup Financial 300% Minupon Princ Protected Nts for Russell 2000 Index

MasterBrand expects FY 2024 Net sales Y/Y increase of low single digits; Adj. EBITDA: $385M-$405M; Adj. Diluted EPS: $1.50-$1.62  VS Est. 1.49

RVLV

Revolve Group shares are trading higher after the company reported better-than-expected Q3 financial results.

Northern Oil &amp; Gas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOG#NYSE">NOG</a>) reported quarterly earnings of $1.40 per share which beat the analyst consensus estimate of $1.20 by 16.67 percent. This is a 19.08 percent decrease over earnings of $1.73 per share from the same period last year. The company reported quarterly sales of $513.54 million which missed the analyst consensus estimate of $542.84 million by 5.40 percent. This is a 0.37 percent increase over sales of $511.65 million the same period last year.

Northern Oil & Gas Q3 Adj $1.40 Beats $1.20 Estimate, Sales $513.54M Miss $542.84M Estimate

TMCI

Treace Medical Concepts shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 sales guidance.

BigBear.ai Affirms 2024 Revenue Guidance $165M-$180M

BigBear.ai Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.07) by 28.57 percent. The company reported quarterly sales of $41.505 million which missed the analyst consensus estimate of $46.030 million by 9.83 percent. This is a 22.12 percent increase over sales of $33.988 million the same period last year.

BigBear.ai Hldgs Q3 2024 GAAP EPS $(0.05) Beats $(0.07) Estimate, Sales $41.505M Miss $46.030M Estimate

Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) reported quarterly earnings of $0.83 per share which beat the analyst consensus estimate of $0.65 by 27.69 percent. The company reported quarterly sales of $625.71 million which beat the analyst consensus estimate of $603.93 million by 3.61 percent. This is a 63.10 percent increase over sales of $383.64 million the same period last year.

Globus Medical Q3 2024 Adj EPS $0.83 Beats $0.65 Estimate, Sales $625.71M Beat $603.93M Estimate

B&G Foods shares are trading lower after the company reported worse-than-expected Q3 financial results and issued FY24 net sales guidance below estimates.

Acadia Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) today announced that it entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million upon the closing of the transaction.
Acadia was granted the PRV in March 2023 following approval by the U.S. Food and Drug Administration (FDA) of DAYBUE&#x2122; (trofinetide) for the treatment of Rett syndrome. DAYBUE was initially licensed by Acadia from Neuren Pharmaceuticals Limited in August 2018. Pursuant to the license agreement, Acadia is required to pay Neuren one-third of the net proceeds.
Acadia plans to invest proceeds from the sale of the PRV to support its commercial operations, R&amp;D programs in central nervous system and rare disease, and future business development.
The transaction is subject to customary closing conditions, including expiration of applicable waiting period under the Hart-Scott Rodino (HSR) Antitrust Improvements Act. Jefferies LLC acted as financial advisor to Acadia on this transaction.

Asset Sales

ACAD

Acadia Pharmaceuticals Enters Into An Agreement To Sell Its Rare Pediatric Disease Priority Review Voucher For $150M

Gulf Island Fabrication (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIFI#NASDAQ">GIFI</a>) reported quarterly earnings of $0.14 per share. The company reported quarterly sales of $37.640 million which missed the analyst consensus estimate of $42.000 million by 10.38 percent. This is a 649.35 percent increase over sales of $5.023 million the same period last year.

GIFI

Gulf Island Fabrication Q3 2024 GAAP EPS $0.14, Sales $37.640M Miss $42.000M Estimate

Ternium Q3 2024 EPADS $0.16, Sales $4.480B Beat $4.446B Estimate

New preclinical data on allogeneic CAR+TCR-T cells rich in stem cell memory T cells (TSCM) and enhanced potency to better target solid tumors will be presented at SITC
Additional profiling of patient responses in P-BCMA-ALLO1 Phase 1 Arm C and preclinical P-CD19CD20-ALLO1 to be presented at ASH
SAN DIEGO, Nov. 5, 2024 /PRNewswire/ --&nbsp;Poseida Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced new preclinical data on allogeneic CAR+TCR-T cells rich in stem cell memory T cells (TSCM), along with platform enhancements aimed at enhancing potency and improving targeting of solid tumors, will be presented at the Society for Immunotherapy of Cancer (SITC) 39th&nbsp;Annual Meeting in Houston, November 6-10.

Biotech

General

PSTX

Poseida Therapeutics To Present Clinical And Preclinical Data On Investigational Allogeneic CAR-T Cell Therapies At SITC 2024 And ASH 2024

Q1 2024 Sales/ Trading Statement Call

Rexel S.A. (RXLSF) Q1 2024 Earnings Call Transcript

Rexel S.A. (RXEEY) Q1 2024 Sales/Trading Statement Call Transcript

Rexel S.A. goes ex dividend Monday

Rexel S.A.: Executing Well Through Challenging End-Market Trends

Rexel S.A. 2024 Q2 - Results - Earnings Call Presentation

Rexel S.A. (RXLSF) Q2 2024 Earnings Call Transcript

French group Rexel turns down QXO's $9.4B acquisition offer

QXO no longer bidding for France's Rexel, considering other US deal - report

Blue Tower Asset Management Q3 2024 Commentary

ABBNY

ENVA

RXEEY

RXLSF

Rexel

Comments

Rexel

Rexel (RXEEY) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO